Qiao, Shuai http://orcid.org/0000-0002-9573-8774
Lee, Chia-Wei http://orcid.org/0000-0002-8925-7421
Sherpa, Dawafuti http://orcid.org/0000-0001-7815-5895
Chrustowicz, Jakub http://orcid.org/0000-0002-3059-1863
Cheng, Jingdong http://orcid.org/0000-0003-4442-377X
Duennebacke, Maximilian
Steigenberger, Barbara
Karayel, Ozge http://orcid.org/0000-0003-2541-1159
Vu, Duc Tung
von Gronau, Susanne
Mann, Matthias http://orcid.org/0000-0003-1292-4799
Wilfling, Florian http://orcid.org/0000-0002-6559-7261
Schulman, Brenda A. http://orcid.org/0000-0002-3083-1126
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SCHU 3196/1-1)
Max-Planck-Gesellschaft (Schulman department)
Article History
Received: 7 October 2021
Accepted: 19 May 2022
First Online: 1 June 2022
Competing interests
: B.A.S. holds additional appointments as an Honorary Professor at Technical University of Munich, Germany and adjunct faculty at St. Jude Children’s Research Hospital, Memphis, TN, USA and is on the Scientific Advisory Boards of Interline Therapeutics and BioTheryX. B.A.S. is co-inventor of intellectual property related to DCN1 inhibitors (unrelated to this work) licensed to Cinsano. The remaining authors declare no competing interests.